N
Nicola Moore
Researcher at Hoffmann-La Roche
Publications - 30
Citations - 6274
Nicola Moore is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Bevacizumab & Gemcitabine. The author has an hindex of 16, co-authored 30 publications receiving 5688 citations. Previous affiliations of Nicola Moore include Genentech.
Papers
More filters
Journal ArticleDOI
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier,Anna Pluzanska,Piotr Koralewski,Alain Ravaud,Sergio Bracarda,Cezary Szczylik,Christine Chevreau,Marek Filipek,Bohuslav Melichar,Emilio Bajetta,Vera Gorbunova,Jacques-Olivier Bay,Istvan Bodrogi,Agnieszka Jagiełło-Gruszfeld,Nicola Moore +14 more
TL;DR: In this article, the authors investigated the combination treatment of the humanised anti-VEGF monoclonal antibody bevacizumab with interferon alfa, and reported a significant improvement in progression-free survival.
Journal ArticleDOI
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
Martin Reck,Joachim von Pawel,Petr Zatloukal,Rodryg Ramlau,Vera Gorbounova,Vera Hirsh,Natasha B. Leighl,J. Mezger,Venice Archer,Nicola Moore,Christian Manegold +10 more
TL;DR: Combining bevacizumab (7.5 or 15 mg/kg) with CG significantly improved PFS and objective response rate and offers clinical benefit for bevicizumAB-eligible patients with advanced NSCLC.
Journal ArticleDOI
AACR project genie: Powering precision medicine through an international consortium
Shawn M. Sweeney,Ethan Cerami,Alexander S. Baras,Trevor J. Pugh,Nikolaus Schultz,Thomas Stricker,James Lindsay,C. Del Vecchio Fitz,Priti Kumari,Christine M. Micheel,K. Shaw,Jianjiong Gao,Nicola Moore,Cyriac Kandoth,Brendan Reardon,Eva M Lepisto,Stuart Gardos,Kristen K. Dang,Justin Guinney,Larsson Omberg,Thomas Yu,Benjamin Gross,Zachary J. Heins,David M. Hyman,Barrett J. Rollins,Charles L. Sawyers,David B. Solit,Deborah Schrag,Victor E. Velculescu,Fabrice Andre,Philippe L. Bedard,Mia Levy,Gerrit A. Meijer +32 more
Journal ArticleDOI
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
Martin Reck,J. von Pawel,Petr Zatloukal,Rodryg Ramlau,Vera Gorbounova,Vera Hirsh,Natasha B. Leighl,J. Mezger,V. Archer,Nicola Moore,Christian Manegold +10 more
TL;DR: Final analysis of AVAiL confirms the efficacy of bevacizumab when combined with cisplatin–gemcitabine, and the PFS benefit did not translate into a significant OS benefit, possibly due to high use of efficacious second-line therapies.
Journal ArticleDOI
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial
Thomas Sandmann,Richard Bourgon,Josep Garcia,Congfen Li,Timothy F. Cloughesy,Olivier Chinot,Wolfgang Wick,Ryo Nishikawa,W. Mason,Roger Henriksson,Frank Saran,Albert Lai,Nicola Moore,Samir Kharbanda,Franklin Peale,Priti S. Hegde,Lauren E. Abrey,Heidi S. Phillips,Carlos Bais +18 more
TL;DR: Retrospective analysis of AVAglio data suggests that patients with IDH1 wild-type proneural glioblastoma may derive an OS benefit from first-line bevacizumab treatment.